Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
21 Things You Ought to Never Tell Your Childless Companion - 2Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 3How AI fixed the James Webb Space Telescope's blurry vision
- 4The 15 Most Motivating TED Discusses All Time
- 5British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- We may be witnessing the messy death of a star in real time
- Surprise! Saturn's huge moon Titan may not have a buried ocean after all
- 'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- Vote in favor of your Favored kind of craftsmanship
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Instructions to Boost Your True capacity with a Brain research Degree
- The Specialty of Compromise: Examples from Reality
